Nexalin Technology Inc (NXL)

$0.33 -0.03 (-7.03%)
Market Cap 7.41M
Revenue (ttm) 300,000.00
Net Income (ttm) -8.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,740.00%
Debt to Equity Ratio 0.00
Volume 99,400
Avg Vol 680,502
Day's Range N/A - N/A
Shares Out 20.58M
Stochastic %K 3%
Beta 3.80
Analysts Strong Sell
Price Target $2.00

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic br...

Industry: Medical Devices
Sector: Healthcare
Phone: 832 260 0222
Address:
1776 Yorktown, Suite 550, Houston, United States
MaskMaker
MaskMaker Jun. 25 at 4:32 AM
$NXL
0 · Reply
Dante_s_Inferno
Dante_s_Inferno Jun. 24 at 3:19 PM
$NXL when is the deadline for rs?
0 · Reply
MaskMaker
MaskMaker Jun. 24 at 5:43 AM
$NXL
0 · Reply
isaacwilliams33
isaacwilliams33 Jun. 23 at 9:13 PM
$NXL has pattern for September/October. Absolute bottom was 18-23cents, 52week low of 30cents. That was the first trade I take with real money actually, If I see itis under 26cents I might pick up a few shares and hold till the Fall.
0 · Reply
MaskMaker
MaskMaker Jun. 23 at 7:31 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 22 at 3:47 PM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 21 at 9:12 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 20 at 7:23 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 19 at 6:03 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 18 at 5:17 AM
$NXL
0 · Reply
Latest News on NXL
Nexalin Technology investigator wins award for neurostimulation research

2026-06-23T15:25:14.000Z - 1 day ago

Nexalin Technology investigator wins award for neurostimulation research

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform

Jun 23, 2026, 8:30 AM EDT - 1 day ago

Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Jun 16, 2026, 9:15 AM EDT - 8 days ago

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

Nexalin Technology completes neurostimulation protocol trial

2026-06-10T13:32:50.000Z - 14 days ago

Nexalin Technology completes neurostimulation protocol trial

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Jun 10, 2026, 9:15 AM EDT - 14 days ago

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Nexalin Technology Registration statement

Jun 8, 2026, 6:56 AM EDT - 16 days ago

Nexalin Technology Registration statement

Nexalin Technology Quarterly report

Jun 8, 2026, 6:56 AM EDT - 16 days ago

Nexalin Technology Quarterly report

Nexalin Technology announces issuance of new U.S. patent

2026-06-04T14:08:10.000Z - 20 days ago

Nexalin Technology announces issuance of new U.S. patent

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Jun 4, 2026, 10:00 AM EDT - 20 days ago

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

May 21, 2026, 8:30 AM EDT - 4 weeks ago

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

May 19, 2026, 8:30 AM EDT - 5 weeks ago

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

Nexalin Technology Quarterly report: Q1 2026

May 8, 2026, 8:00 AM EDT - 6 weeks ago

Nexalin Technology Quarterly report: Q1 2026

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Apr 28, 2026, 9:15 AM EDT - 2 months ago

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

Nexalin Technology enters agreements to advance HALO Clarity trial

2026-04-22T14:03:36.000Z - 2 months ago

Nexalin Technology enters agreements to advance HALO Clarity trial

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

Apr 22, 2026, 9:35 AM EDT - 2 months ago

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

Nexalin Technology advances FDA Alzheimer’s strategy

2026-04-15T14:21:51.000Z - 2 months ago

Nexalin Technology advances FDA Alzheimer’s strategy

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Apr 15, 2026, 10:00 AM EDT - 2 months ago

Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Apr 14, 2026, 8:30 AM EDT - 2 months ago

Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Apr 9, 2026, 7:47 AM EDT - 2 months ago

Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

Nexalin Technology price target lowered to $2 from $4 at Maxim

2026-04-07T13:31:54.000Z - 2 months ago

Nexalin Technology price target lowered to $2 from $4 at Maxim

Nexalin Technology Annual report: Q4 2025

Mar 25, 2026, 8:00 AM EDT - 3 months ago

Nexalin Technology Annual report: Q4 2025

Nexalin Technology Slides: Investor presentation

Mar 1, 2026, 7:00 AM EST - 4 months ago

Nexalin Technology Slides: Investor presentation

Nexalin announces continued advancement toward trial evaluating HALO Clarity

2026-02-24T13:34:50.000Z - 4 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

Nexalin announces continued advancement toward trial evaluating HALO Clarity

2026-02-24T13:29:27.000Z - 4 months ago

Nexalin announces continued advancement toward trial evaluating HALO Clarity

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

Feb 24, 2026, 8:07 AM EST - 4 months ago

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

Nexalin ‘commended’ recent Congressional initiative on neurostim research

2026-02-23T13:33:27.000Z - 4 months ago

Nexalin ‘commended’ recent Congressional initiative on neurostim research

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Feb 23, 2026, 8:18 AM EST - 4 months ago

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

Nexalin Technology launches AI-designed virtual clinic platform NeuroCare

2026-02-05T13:46:39.000Z - 4 months ago

Nexalin Technology launches AI-designed virtual clinic platform NeuroCare

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

Feb 5, 2026, 8:37 AM EST - 4 months ago

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care

Nexalin Technology highlights research validating neurostimulation technology

2026-02-02T13:56:38.000Z - 5 months ago

Nexalin Technology highlights research validating neurostimulation technology

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Feb 2, 2026, 8:45 AM EST - 5 months ago

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

Nexalin Technology announces publication of peer-reviewed study on DIFS

2026-01-14T14:05:14.000Z - 5 months ago

Nexalin Technology announces publication of peer-reviewed study on DIFS

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Jan 14, 2026, 9:00 AM EST - 5 months ago

Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

Nexalin Technology completes FDA Q-sub meeting for Gen-2 SYNC neurostimulation

2025-12-03T13:05:47.000Z - 7 months ago

Nexalin Technology completes FDA Q-sub meeting for Gen-2 SYNC neurostimulation

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Dec 3, 2025, 8:00 AM EST - 7 months ago

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

Dec 2, 2025, 8:00 AM EST - 7 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4

Nexalin announces results for 15 mA neurostimulation device

2025-11-18T14:42:34.000Z - 7 months ago

Nexalin announces results for 15 mA neurostimulation device

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nov 18, 2025, 9:00 AM EST - 7 months ago

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nexalin Technology Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

Nexalin Technology Quarterly report: Q3 2025

Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel

2025-11-13T14:21:40.000Z - 7 months ago

Nexalin Technology appoints Carmi Masha as exclusive distributor in Israel

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nov 13, 2025, 9:15 AM EST - 7 months ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nexalin Technology announces FDA acceptance of Q-Sub for Gen-2 SYNC

2025-11-05T13:40:36.000Z - 8 months ago

Nexalin Technology announces FDA acceptance of Q-Sub for Gen-2 SYNC

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Nov 5, 2025, 8:30 AM EST - 8 months ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Nexalin Technology announces regulatory approval to sell Gen 2 SYNC

2025-10-30T12:46:01.000Z - 8 months ago

Nexalin Technology announces regulatory approval to sell Gen 2 SYNC

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

2025-10-21T13:10:34.000Z - 8 months ago

Nexalin announces three studies published on Gen-2 Nexalin DIFS technology

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Oct 21, 2025, 9:00 AM EDT - 8 months ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Nexalin Technology appoints Robert Rothstein to Scientific Advisory Board

2025-10-13T12:40:42.000Z - 9 months ago

Nexalin Technology appoints Robert Rothstein to Scientific Advisory Board

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 13, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 10, 2025, 8:00 AM EDT - 9 months ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Oct 8, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Sep 25, 2025, 8:30 AM EDT - 9 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 25, 2025, 9:00 AM EDT - 10 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Nexalin Technology Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 11 months ago

Nexalin Technology Quarterly report: Q2 2025

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

Aug 1, 2025, 8:30 AM EDT - 11 months ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

Nexalin Technology Proxy statement: Proxy filing

Jun 17, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Proxy statement: Proxy filing

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 28, 2025, 10:00 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 13, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

Nexalin Technology Quarterly report: Q1 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Quarterly report: Q1 2025

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 6, 2025, 2:40 PM EDT - 1 year ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 5, 2025, 8:20 AM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

May 1, 2025, 10:30 AM EDT - 1 year ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 24, 2025, 9:00 AM EDT - 1 year ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 23, 2025, 9:15 AM EDT - 1 year ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Nexalin Technology Registration statement: Registration filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Registration statement: Registration filing

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 14, 2025, 12:30 PM EDT - 1 year ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Apr 2, 2025, 8:30 AM EDT - 1 year ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 26, 2025, 8:30 AM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Nexalin Technology Annual report: Q4 2024

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Nexalin Technology Annual report: Q4 2024

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Mar 3, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 28, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 26, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 18, 2025, 8:30 AM EST - 1 year ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 10, 2025, 9:00 AM EST - 1 year ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Feb 3, 2025, 8:30 AM EST - 1 year ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Nexalin Technology Registration statement: Registration filing

Jan 30, 2025, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Jan 23, 2025, 11:00 AM EST - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin Technology Registration statement: Registration filing

Jan 10, 2025, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nexalin Technology Registration statement: Registration filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

Nexalin Technology Registration statement: Registration filing

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nexalin Technology Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Nexalin Technology Quarterly report: Q3 2024

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

MaskMaker
MaskMaker Jun. 25 at 4:32 AM
$NXL
0 · Reply
Dante_s_Inferno
Dante_s_Inferno Jun. 24 at 3:19 PM
$NXL when is the deadline for rs?
0 · Reply
MaskMaker
MaskMaker Jun. 24 at 5:43 AM
$NXL
0 · Reply
isaacwilliams33
isaacwilliams33 Jun. 23 at 9:13 PM
$NXL has pattern for September/October. Absolute bottom was 18-23cents, 52week low of 30cents. That was the first trade I take with real money actually, If I see itis under 26cents I might pick up a few shares and hold till the Fall.
0 · Reply
MaskMaker
MaskMaker Jun. 23 at 7:31 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 22 at 3:47 PM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 21 at 9:12 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 20 at 7:23 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 19 at 6:03 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 18 at 5:17 AM
$NXL
0 · Reply
NapoleonBull
NapoleonBull Jun. 17 at 2:23 PM
$NXL I assembled their conference table in Houston Texas, saw a happy crazy client, i figure good to buy/hold.
1 · Reply
MaskMaker
MaskMaker Jun. 17 at 5:43 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 17 at 1:15 AM
$NXL
0 · Reply
INandAROUNDandOUT
INandAROUNDandOUT Jun. 16 at 4:30 PM
$NXL https://x.com/RedChip/status/2066859695185301617?s=20 This is real futuristic healing and just the beginning.
0 · Reply
focafoca99
focafoca99 Jun. 16 at 1:31 PM
$NXL exhibits two clinical abstracts accepted for the 2026 NYC Neuromodulation Conference, highlighting anxiety and insomnia trial results.
0 · Reply
MrTicker
MrTicker Jun. 16 at 1:20 PM
$NXL Nexalin Technology To Present Clinical Data Showing 77.8% Anxiety Response Rate, Durable 8-Week Benefits, And No Serious Adverse Events From Its 15 mA, 77.5 Hz DIFS Deep-Brain Stimulation Platform, At 2026 NYC Neuromodulation Conference BENZINGA 8:18 AM ET 6/16/2026
0 · Reply
MaskMaker
MaskMaker Jun. 16 at 7:13 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 15 at 4:19 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 15 at 1:00 AM
$NXL
0 · Reply
MaskMaker
MaskMaker Jun. 13 at 8:17 PM
$NXL
0 · Reply
Dante_s_Inferno
Dante_s_Inferno Jun. 12 at 8:23 PM
$NXL this stock is like a kick in the nuts
0 · Reply
MaskMaker
MaskMaker Jun. 12 at 4:44 AM
$NXL
0 · Reply